



QC-01-175-1



Chemical Formula: C<sub>33</sub>H<sub>34</sub>N<sub>6</sub>O<sub>7</sub>  
Molecular Weight: 626.67

Category	Parameter	Description
Compound	Name	QC-01-175-1
	Citation	Silva et al. eLife 2019;8:e45457. DOI: <a href="https://doi.org/10.7554/eLife.45457">https://doi.org/10.7554/eLife.45457</a>
	Chemical descriptors	O=C(NCCOCCOCCNC1=CC=CC2=C1C(N(C2=O)C3CCC(NC3=O)=O)=O)CCC4=CC5=C(C6=C(C=CN=C6)N5)C=C4
	Chemical name	N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)amino)ethoxy)ethoxy)ethyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide
	Entries in chemical databases	N/A
	Availability	N/A
	Papers that use the compounds	N/A
	Additional comments	Negative control QC-03-075-1 also available
<i>In vitro</i> profiling	Target (potency)	P-Tau DC <sub>50, 24 h</sub> ~ 100 nM in patient iPSC derived FTD neurons harboring MAPT A152T mutation
	Target (potency)	N/A
	Selectivity	iMiD targets ZFP91, ZN653, ZN827 also degraded at 4 h, 1 μM in patient iPSC derived FTD neurons harboring MAPT A152T mutation
	Potential reactivity	N/A
	SAR	Manuscript in preparation
	Mechanism of inhibition	Targeted degradation
	Structure of target-probe complex	N/A
Cellular profiling	Validation of cellular target	Western blot, ELISA assay
	Validation of cellular specificity	Global proteomics
	Additional comments	
Pharmacodynamics		
Pharmacokinetics		



Synthetic scheme

**Scheme 1.** Synthesis route for the tau degrader QC-01-175.